Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

11

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

DNA topoisomerase II alpha

11

A673

8

DNA topoisomerase II

8

HepG2

8

Human ovarian cancer cell line

8

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

11

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1974

8

1979

3

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

AIDS-related Kaposi’s sarcoma

8

Glioblastoma

8

Kaposi’s sarcoma

8

Locally advanced or unresectable soft tissue sarcoma

8

Metastatic non-small cell lung cancer

8

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

11

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

8

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

The Regents of The University of Colorado

8

Hahn, A.|Dumaitre, P.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

12

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

12

FDA UNII

12

PUBCHEM

12

NCI_THESAURUS

11

DRUG BANK

10

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES

2

OTHER ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Anthracyclines and related substances

2

Combinations of antineoplastic agents

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

9

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 12 results

First page disabled
Previous page disabled
1
Next page
Next page

DAUNORUBICIN

ZS7284E0ZP

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1979

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase I

DNA topoisomerase II alpha

Multidrug resistance-associated protein 1

Conditions:

Acute lymphoblastic leukemia

Acute myeloblastic leukemia

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar ...

to doxorubicin, daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death.

DOXORUBICIN

80168379AG

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

PHENYLHYDROXYLAMINE

282MU82Z9A

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

DAUNORUBICIN CITRATE

5L84T2Z6NP

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1979

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase I

DNA topoisomerase II alpha

Multidrug resistance-associated protein 1

Conditions:

Acute lymphoblastic leukemia

Acute myeloblastic leukemia

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar ...

to doxorubicin, daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death.

DAUNORUBICIN HYDROCHLORIDE

UD984I04LZ

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1979

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase I

DNA topoisomerase II alpha

Multidrug resistance-associated protein 1

Conditions:

Acute lymphoblastic leukemia

Acute myeloblastic leukemia

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar ...

to doxorubicin, daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death.

AVA-6000

7XPB9B6MUA

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

ZOPTARELIN DOXORUBICIN ACETATE

4IA03SIO30

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

DOXORUBICIN CITRATE

AJQ2ZNG2WL

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

ALDOXORUBICIN HYDROCHLORIDE

S098K6HGD9

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

ALDOXORUBICIN

C28MV4IM0B

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

Showing 1 - 10 of 12 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1